Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 1,390 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo sold 1,390 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the sale, the senior vice president now owns 98,568 shares of the company’s stock, valued at $3,405,524.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Dyne Therapeutics Trading Up 6.0 %

Shares of DYN stock opened at $36.41 on Friday. The firm has a fifty day simple moving average of $41.17 and a two-hundred day simple moving average of $33.49. Dyne Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $47.45. The firm has a market capitalization of $3.18 billion, a PE ratio of -9.17 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.02. On average, equities analysts predict that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Institutional Trading of Dyne Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Concurrent Investment Advisors LLC bought a new stake in shares of Dyne Therapeutics in the 1st quarter worth $573,000. Sei Investments Co. purchased a new position in Dyne Therapeutics during the first quarter worth about $693,000. Rafferty Asset Management LLC grew its position in Dyne Therapeutics by 17.7% in the 4th quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock worth $2,182,000 after purchasing an additional 24,632 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in Dyne Therapeutics in the 1st quarter worth about $810,000. Finally, Commodore Capital LP purchased a new stake in Dyne Therapeutics in the 4th quarter valued at about $11,970,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. Morgan Stanley increased their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Guggenheim boosted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Finally, Piper Sandler raised their price target on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.